Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816
Chul Ha
Abstract Talk
Baseline PET features as predictors of outcome in advanced HL : A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)
Catherine Guezennec
Abstract Talk
B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)
Alexander Fossa
09:15 – 10:15
Room: Großer Saal
Scientific Symposium
(by Celgene GmbH)
CAR T Cell Therapies: Hype Or Hope?
Survival by race/ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: A pooled analysis of contemporary Children’s Oncology Group trials
Justine Kahn
Abstract Talk
Safety and early response to the first 2 cycles of Brentuximab Vedotin substituting vincristine in the OEPA / COPDAC regimen for high risk pediatric Hodgkin Lymphoma (HL)
Monika Metzger
Abstract Talk
The feasibility of deep inspiration breath-hold in children: Results of the TEDDI pilot study
Maja Maraldo
12:15 – 13:45
Room: Großer Saal
Scientific Symposium
(by MSD)
Checkpointblockade in Lymphomas
Andreas Engert
12:15–12:35
Basics in immunotherapy for lymphomas
Dominik Wolf
12:35–12:55
PD-1 blockade current and future aspects of cHL therapy
Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma: follow-up results from the phase 1/2 study
Alex Herrera
Abstract Talk
A Phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese Patients with Relapsed/Refractory classic Hodgkin Lymphoma
Yuqin Song
Poster Pitch
A phase II study of Pembrolizumab (PEM) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (cHL): interim results
Pamela Allen
Abstract Talk
Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
Jonathan Friedberg
Abstract Talk
Allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory classical Hodgkin Lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate
Second Autologous Stem Cell Transplantation (ASCT) for Relapsed or Refractory (R/R) Hodgkin Lymphoma (HL) after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Carmen Martinez
Abstract Talk
Bendamustine, Gemcitabine, and Dexamethasone (BGD) Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) Is Effective Treatment for Patients with Relapsed/Refractory Hodgkin Lymphoma (rHL) – Results of the Polish Lymphoma Research Group
Ewa Paszkiewicz-kozik
Poster Pitch
Long Term Safety and Efficacy of Combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)
Catherine Diefenbach
Poster Pitch
PD-1 blockade for Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation
Anna Sureda
Abstract Talk
Five-Year Progression-Free Survival Outcomes From a Pivotal Phase 3 Study of Consolidative Brentuximab Vedotin After Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression (AETHERA).
Craig H. Moskowitz
Abstract Talk
Relapse after Early-Stage Favorable Hodgkin Lymphoma: Disease Characteristics, Treatment Strategies and their Outcome